Alkem Laboratories Ltd

Alkem Laboratories maintains a conservative capital structure with a debt-to-equity ratio of 0.15, indicating low leverage relative to shareholder equity. The company holds INR 17.33 billion in cash and equivalents against INR 20.47 billion in long-term debt, resulting in a net cash position that is technically negative after subtracting total debt, as flagged in the risk assessment. Liquidity is supported by a current ratio of 2.55, suggesting adequate short-term assets to cover liabilities. Operating cash flow stands at INR 19.63 billion, while free cash flow is INR 15.02 billion, reflecting strong cash generation capabilities despite capital expenditures of INR 6.17 billion.

Profitability metrics demonstrate efficient capital utilization, with a return on equity of 16.66% and a return on assets of 11.03%. The company generated INR 23.02 billion in net income from INR 147.12 billion in revenue, indicating a robust net profit margin. Gross profit of INR 96.20 billion and operating income of INR 24.48 billion further underscore strong operational efficiency and cost management. Without cohort median data for direct comparison, these returns appear solid for a pharmaceutical manufacturer, though specific industry benchmarks are not provided in the input.